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Abstract
Here, we report the case of a patient who developed protamine shock during a transcatheter aortic valve implant
(TAVI) procedure, which was diagnosed by intraoperative transesophageal echocardiography (TEE). A 77-year-old
man with symptomatic severe aortic stenosis and reduced left ventricular (LV) function underwent TAVI under
general anesthesia. During the procedure, a transcatheter heart valve (THV) was deployed via the transfemoral
approach, without any other major complications. The entire device system was then removed, and protamine
sulfate was administered intravenously in 2 min.
Two minutes after the protamine administration, severe hypotension occurred. TEE did not reveal THV malfunction
or any other major complications. However, comparison of the TEE image obtained before protamine
administration and that obtained 2 min after protamine administration showed right ventricular (RV) dilatation, RV
free wall motion abnormality, and LV volume reduction, without any electrocardiographic changes. We diagnosed
this as protamine shock and bolus infusions of phenylephrine and norepinephrine were administered, and chest
compressions were initiated immediately. After 1 min, hypotension as well as the right and left ventricular size and
dysfunction immediately reverted to baseline. The severe systemic hypotension resolved as well. Thereafter, he
recovered from anesthesia without other complications.
This case showed the clinical features of protamine shock with acute pulmonary hypertension. The TEE images, in
this case, should be a reminder for all doctors who perform intraoperative TEE for patient monitoring when they
perform procedures to treat structural heart diseases.
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Background
Protamine is the mainstay drug for heparin neutralization
during cardiac surgery, structural heart disease (SHD)
intervention, or coronary intervention [1]. Transcatheter
aortic valve implantation (TAVI), a common minimally
invasive approach for treating severe aortic valve stenosis
(AS), is currently performed worldwide in elderly and
high-risk patients [2]. Here, we present a case of
protamine shock during a TAVI procedure in which many
other causes of hypotension were considered and intraop-
erative transesophageal echocardiography (TEE) was
useful for arriving at the diagnosis.
Case presentation
A 77-year-old man with symptomatic severe AS and
reduced left ventricular (LV) function underwent TAVI
under general anesthesia. During the procedure, dobu-
tamine (2–5 μg/kg/min) and nicorandil (3 mg/h) were
continuously infused to maintain hemodynamic stabil-
ity. A transcatheter heart valve (THV) (SAPIEN XT
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26 mm) was deployed via the transfemoral approach
with an electrocardiographic change in the left bundle
branch block (LBBB), without any other major compli-
cations (Fig. 1a, b). Thereafter, the entire device system
was removed, and protamine sulfate (60 mg) was
administered intravenously in 2 min to achieve appro-
priate hemostasis.
Two minutes after the protamine administration,
severe hypotension occurred (30/10 mmHg). TEE did
not reveal THV malfunction or any other major
complications; however, comparison of the TEE image
obtained before the protamine administration (Fig. 2a,
Additional file 1: Video 1) and that obtained 2 min after
the protamine administration showed right ventricular
(RV) dilatation, RV free wall motion abnormality, and
LV volume reduction (Fig. 2b, Additional file 2: Video 2)
without any electrocardiographic changes, indicative of a
persistent LBBB, and pulse oximetry changes. We diag-
nosed this as protamine shock, and then, three bolus
infusions of phenylephrine (0.1 mg) followed by a bolus
infusion of norepinephrine (50 μg) were immediately
administered, and chest compressions were initiated
simultaneously. After 1 min, hypotension as well as the
right and left ventricular size and dysfunction
immediately reverted to baseline (Fig. 2c, Additional file 3:
Video 3). The severe systemic hypotension resolved as
well. Thereafter, he recovered from anesthesia without
other complications and blood gas abnormalities.
Discussion
This case showed the clinical features of protamine shock
by acute pulmonary hypertension (APH), a rare cause of
hypotension during the TAVI procedure. The transfemoral
approach TAVI procedure has several well-known causes
Fig. 1 Aortography and TEE images after THV implantation. Aortography (a) and short-axis intraoperative TEE (b) images of the transcatheter heart
valve (SAPIEN XT 26 mm) showing only trivial paravalvular leakage, without any other complications. THV transcatheter heart valve
Fig. 2 Mid-esophageal four-chamber TEE images collected during the procedure. a TEE image after THV deployment showing normal RV size (RV
Dd/Ds = 33.0/26.4 mm). b TEE image collected 2 min after protamine administration demonstrating RV dilatation (yellow arrow) (RV Dd/Ds = 37.4/
34.6 mm) and left ventricular (LV Dd/Ds = 46.0/36.6 mm) volume reduction. Severe systemic hypotension was observed at the same time. c TEE
image after 1 min of chest compressions (approximately 5 min after protamine administration) demonstrating that the RV and LV size and wall
motion had returned to baseline (RV Dd/Ds = 30.9/25.4 mm, LV Dd/Ds = 57.2/49.4 mm). Dd dimension end-diastole, Ds dimension end-systole, LV
left ventricle, RV right ventricle, TEE transesophageal echocardiography
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of systemic hypotension such as access site bleeding, car-
diac tamponade, aortic root rupture, coronary obstruction,
aortic regurgitation, mitral regurgitation, and THV mal-
function [3]. TEE images can be used to assess these major
complications immediately [4]. In this case, we found rare
images showing RV dilatation and free wall motion abnor-
mality followed by an LV volume reduction that suggested
the existence of APH. These images indicated several differ-
ential diagnoses such as protamine-induced APH, acute
pulmonary embolism, and RV infarction. First, we excluded
the possibility of RV infarction due to coronary obstruction.
Although an LBBB appeared after THV deployment, the
normal RV free wall motion persisted prior to the develop-
ment of hypotension. In addition, there were no electrocar-
diographic changes around the time of the severe
hypotension. We ultimately diagnosed protamine-induced
APH rather than a pulmonary embolism, considering of
the time course in which the RV dysfunction recovered
after only 1 min of chest compressions.
Protamine remains the mainstay drug for heparin
neutralization during coronary intervention or cardiac
surgery, and it occasionally causes transient hypotension
known as “protamine shock” in clinical settings [5].
Protamine shock has three different causes: APH, ana-
phylactoid reaction, and histamine release followed by
rapid injection [5, 6]. APH is a clinical diagnosis and
uncommon complication of protamine administration
which rarely occurs with an incidence of 0.06 % [5, 7].
However, it is severe and life threatening. Multiple
immunological and non-immunological processes can
trigger acute pulmonary vasoconstriction, which increases
pulmonary artery pressure, thereby resulting in RV dilata-
tion and dysfunction followed by an LV volume reduction
due to poor LV filling and, consequently, systemic
hypotension [6–8]. The TEE images, in this case, were
able to capture this pathognomonic biventricular failure,
which helped us with the diagnosis.
There are several suggested potential risk factors for
protamine shock, including a history of vasectomy, previ-
ous protamine exposure, vertebrate fish allergy, and preex-
isting pulmonary hypertension [5, 9]. It is interesting to
note that, despite the fact that our patient did not have
any risk factors and that we carefully and slowly injected
the protamine, he experienced protamine shock. Fortu-
nately, his blood pressure recovered within 5 min, without
the need for an artificial heart-lung machine or percutan-
eous cardiopulmonary support system. This result might
be due to the fact that the amount of protamine sulfate
was only one third (60 mg) of that used in general cardiac
surgery. The numbers of TAVI and SHD intervention
procedures, which require the use of protamine, per-
formed in Japan have drastically increased in recent years.
Accordingly, clinicians should carefully perform intraoper-
ative TEE monitoring for protamine shock.
Conclusions
Here, we reported the case of a patient who developed
protamine shock with APH during a TAVI procedure in
which TEE was useful for making the diagnosis. The im-
ages obtained, in this case, should remind all doctors to
perform intraoperative TEE monitoring during TAVI
and SHD procedures whenever protamine is used.
Additional files
Additional file 1: Video 1. TEE moving image after THV deployment.
Normal RV size and RV free wall motion in the mid-esophageal
four-chamber TEE view after THV deployment. RV, right ventricle; TEE,
transesophageal echocardiography; THV, transcatheter heart valve.
(AVI 3462 kb)
Additional file 2: Video 2. TEE moving image 2 min after protamine
administration. RV dilatation, RV free wall motion abnormality, and LV
volume reduction in the mid-esophageal four-chamber TEE view 2 min
after protamine administration. LV, left ventricle. (AVI 5923 kb)
Additional file 3: Video 3. TEE moving image after 1 min of chest
compressions. Recovered size and wall motion of RV and LV to baseline
in the mid-esophageal four-chamber TEE view after 1 min of chest
compressions. (AVI 2758 kb)
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